Canaccord Genuity Maintains Buy on TransMedics Gr, Lowers Price Target to $109
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has maintained a Buy rating on TransMedics Group (NASDAQ:TMDX) but has lowered the price target from $169 to $109.
October 29, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Canaccord Genuity has maintained a Buy rating on TransMedics Group but lowered the price target from $169 to $109, indicating a more cautious outlook.
The maintenance of a Buy rating suggests continued confidence in the company's prospects, but the significant reduction in the price target from $169 to $109 indicates a more cautious outlook, likely due to revised expectations or market conditions. This could lead to a short-term negative impact on the stock price as investors adjust to the new target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100